DMAA earnings: real EPS beat/miss history, P/E 52.15. Updated 2026-07-23.
Drugs Made In America Acquisition (DMAA) Research Hub
Drugs Made In America Acquisition (DMAA) trades on NASDAQ, US in the Financial Services (Shell Companies) sector. As of 2026-09-11, shares last closed at 10.8 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 52.15, market cap 0.36B. This hub links to the full technical, earnings and options research available for DMAA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Financial Services (Shell Companies) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 10.8 USD (0.00%) |
| 52-week range | 10.61 USD – 10.8 USD |
| Trend regime | Range |
| 14-day RSI | 84.6 (Overbought) |
| Trailing P/E | 52.15 |
| Market cap | 0.36B |
| Dividend yield | 0.00% |
Available research for DMAA
Covered Call on DMAA: how it works, illustrative setup around the real 10.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DMAA: how it works, illustrative setup around the real 10.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DMAA: how it works, illustrative setup around the real 10.8 USD price, max profit/loss, breakeven and when to use it. Educational.
DMAA technical analysis: range, last 10.8 USD, RSI 84.6, 52w range 10.61 USD–10.8 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DMAA in?
Drugs Made In America Acquisition (DMAA) is classified under Financial Services (Shell Companies), listed on NASDAQ, US.
Is DMAA in an uptrend or downtrend?
As of 2026-09-11, DMAA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DMAA's trailing P/E ratio?
DMAA's trailing P/E is 52.15, with a market cap of 0.36B. See the earnings research page for full valuation detail.